Hematologic disorder

This early-stage trial tested a new vaccine against Plasmodium vivax malaria, given with an adjuvant to boost immune response. It involved 25 healthy adults in the UK to check safety and immune reactions. The study was terminated early, so full results are not available.

This study tests a drug called epcoritamab, given alone or with another drug (lenalidomide), in elderly patients with a type of lymphoma (DLBCL) who cannot receive standard chemotherapy. The goal is to see how well the treatment shrinks tumors and how safe it is. All 111 particip…

This study tests whether adding a three-drug combination (ixazomib, lenalidomide, and dexamethasone) to zoledronic acid after radiation therapy can prevent solitary plasmacytoma of bone from turning into multiple myeloma. Participants receive either the drug combo plus zoledronic…

This phase 2 study tests whether combining magrolimab and pembrolizumab can shrink or eliminate tumors in people with classic Hodgkin lymphoma that has come back or not responded to at least two prior treatments. Magrolimab targets a 'don't eat me' signal on cancer cells, while p…

This study tests an experimental treatment called GLPG5101 for people with B-cell non-Hodgkin lymphoma that has come back or not responded to standard therapy. The treatment is a cell therapy made at the hospital. The study has two phases: first, finding the best dose with the fe…

This early-phase trial tested a combination of two immune-boosting drugs, relatlimab and nivolumab, in children and young adults with Hodgkin or non-Hodgkin lymphoma that had come back or not responded to treatment. The goal was to check safety, drug levels, and whether the tumor…

This study provides continued access to itacitinib for 18 patients who were already benefiting from the drug in earlier trials. Participants have myelofibrosis, chronic graft-versus-host disease, or bronchiolitis obliterans after lung transplant. They continue their same dose as …

This early-stage trial tested a combination of two targeted drugs—tagraxofusp-erzs and gemtuzumab ozogamicin—in 7 patients with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find a safe dose and see if the combination could control the d…

This study compared two treatments to reduce bleeding after heart valve surgery: a concentrated clotting drug (PCC) versus fresh frozen plasma (FFP). The trial planned to enroll 476 adults undergoing elective valve surgery. It was terminated early, so the full comparison was not …

This study tested an experimental drug called REGN7257 in 17 people with severe aplastic anemia, a rare condition where the bone marrow stops making enough blood cells. The drug was given to patients whose disease did not get better or came back after standard immune-suppressing …

This early-stage study tested a new type of cell therapy called LUCAR-B68 in 8 adults with multiple myeloma that had come back or stopped responding to treatment. The therapy targets a protein called BCMA on cancer cells and is designed to be used without needing to match the pat…

This study tested an oral medication, NX-13, in 81 adults with moderate to severe ulcerative colitis. Participants received either NX-13 or a placebo for 12 weeks, with a long-term follow-up option. The trial was terminated early, so the full results are not available, but the da…

This study tests a drug called loncastuximab tesirine in adults with B-cell lymphomas that have returned or not responded to prior treatment. The drug works like a smart bomb, attaching to a marker on cancer cells and delivering chemotherapy directly to them. The main goal is to …

This early-stage trial tests a one-time treatment called BE-101 for adults with severe hemophilia B. The therapy uses a person's own blood cells, modified with CRISPR gene editing, to continuously produce the missing clotting factor. The goal is to reduce or prevent bleeding epis…

This early-stage trial tested a new drug called tomivosertib in 8 adults with acute myeloid leukemia (AML) that had come back or not responded to prior treatments. The goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.

This phase 2 trial tested a combination of two drugs, venetoclax and rituximab, as a first treatment for people over 60 with mantle cell lymphoma. The goal was to see if this chemo-free approach could shrink or control the cancer. However, the study was stopped early after enroll…

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…

This study tested a drug called siplizumab alongside a stem cell transplant for people with severe sickle cell disease. The goal was to see if it could prevent the body from rejecting the new cells and reduce a serious side effect called graft-versus-host disease. Only one person…

This study tested a drug called selinexor in 17 people with a rare bone marrow cancer (myelofibrosis) that did not respond to or could not tolerate standard JAK inhibitor treatments. The main goal was to see if the drug could shrink an enlarged spleen by at least 35%. The trial w…

This pilot study tested a new drug called sEphB4-HSA combined with standard chemotherapy (azacitidine or decitabine) in 7 patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia that had returned or not responded to prior treatment. The …

This early-phase study tested an off-the-shelf natural killer (NK) cell therapy called SAR445419 in adults with acute myeloid leukemia that returned or didn't respond to treatment. Participants received chemotherapy followed by the NK cells to see if it was safe and could help co…

This Phase 2 trial tested a two-step treatment for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. First, patients received a stem cell transplant using their own cells, followed by an infusion of CAR-T cells (a type of immune cell therapy). The goal was to se…

This study tested a combination of two drugs, venetoclax and azacitidine, in 34 adults with high-risk blood cancers (MDS or CMML) that returned or didn't respond to earlier treatment. The goal was to find the safest dose and see if the combo could shrink or control the cancer. Th…

This study tested whether adding venetoclax and azacitidine after a stem cell transplant could help people with acute myeloid leukemia (AML) live longer. It included adults and teens who had recently received a transplant. The trial was stopped early, so the full benefits and ris…

This phase 2 trial aimed to see if infliximab and intravenous immunoglobulin (IVIG) could help cancer patients with severe lung inflammation that didn't respond to steroids. Only one patient was enrolled before the study was terminated, so no meaningful results were obtained. The…

This early-phase trial tested whether adding the targeted drug ivosidenib to standard FLAG chemotherapy could help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML). The study aimed to find the best dose and check for side effects in patients whose c…

This early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped earl…

This study tested two drugs, encorafenib and binimetinib, given before surgery to people with stage IIIB-D melanoma that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was stopped early after enrolling on…

This phase 3 trial tested whether adding asciminib to the standard drug imatinib could help people with chronic myeloid leukemia (CML) achieve a deep remission and safely stop all medication. Only 8 patients were enrolled before the study was terminated early, making it too small…

This early-stage study tested a new drug called SAR445514, which helps the body's natural killer (NK) cells attack cancer cells in people with multiple myeloma or light-chain amyloidosis that had returned or stopped responding to other treatments. The study was terminated early, …

This study tested a reduced-intensity bone marrow transplant, or 'mini transplant,' for people with blood cancers like lymphoma and leukemia. The transplant used marrow from a relative and was combined with chemotherapy drugs to help the donor cells take hold. Only 15 people took…

This phase II trial tested whether the drug ibrutinib could prevent chronic graft-versus-host disease (GVHD) in adults who had received a donor stem cell transplant. Only 2 people enrolled before the study was terminated early. Because of the very small number of participants, no…

This phase 1 trial tested the safety of the drug lenalidomide as maintenance therapy after a reduced-intensity stem cell transplant for multiple myeloma. Only 13 people took part, and the study was terminated early. The goal was to see if lenalidomide could help prevent the cance…

This study tested a drug called vibecotamab in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose cancer did not respond to or came back after standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells.…

This early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …

This study tested a new experimental drug called GEN3014 (HexaBody-CD38) in people with multiple myeloma and other blood cancers that had returned or become resistant to treatment. The main goal was to check safety and find the right dose. The trial was terminated early, so the f…

This study looked at using umbilical cord blood transplants after strong chemotherapy and radiation to treat various blood cancers like leukemia and lymphoma. It involved 200 participants and aimed to see how many were alive one year after transplant. The trial was stopped early,…

This study tested a new drug called Vodobatinib (K0706) in people with chronic myeloid leukemia or a related leukemia who had not responded to at least three other treatments. The trial was split into parts: first in healthy volunteers to check safety, then in patients to find th…

This phase 2 trial tested two different drug combinations to prevent graft-versus-host disease (GVHD) in 150 people with blood cancers receiving a stem cell transplant from an unrelated donor. Both combinations used cyclosporine and sirolimus, plus either mycophenolate mofetil or…

This study looked at adding a targeted drug called venetoclax to low-intensity chemotherapy for adults with acute lymphoblastic leukemia (ALL) that came back or didn't respond to treatment. The goal was to find the safest dose and see if the combination could help control the dis…

This study tested a combination of two drugs, ixazomib and daratumumab, without using steroids (dexamethasone) in elderly patients (65 and older) whose multiple myeloma had returned after previous treatments. The goal was to see if this gentler approach could effectively control …

This early-stage trial tested a drug called DS-2325a in 9 adults with Netherton syndrome, a rare genetic condition causing severe skin redness, scaling, and allergies. The study aimed to check safety and whether the drug could help control the disease. However, the trial was term…

This early-phase trial tested an experimental drug called HEC89736 in people with B-cell blood cancers that had returned or stopped responding to treatment. The study aimed to check the drug's safety and how the body processes it. Only 5 people took part before the trial was term…

This pilot study tested adding the targeted drug venetoclax to standard chemotherapy (FLAG or CLAG) for people with newly diagnosed secondary acute myeloid leukemia (sAML), a challenging blood cancer. The goal was to see if the combination could improve complete remission rates. …

This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …

This early-stage study tested a new drug, PF-08046044/SGN-35C, in people with advanced lymphomas (Hodgkin and non-Hodgkin types) who had no other treatment options. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This study tested a combination of two drugs, ibrutinib and ixazomib, in 21 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the combo could shrink or control the cancer. The trial was stopped early, so results are limited, but the approach a…

This study tested a combination of two drugs, ixazomib and romidepsin, for people with a rare type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to treatment. The trial was stopped early after enrolling only 11 participants, so the high…

This study looked at whether adding the drug ixazomib to lenalidomide and dexamethasone can help people with multiple myeloma stay in remission longer after their first round of chemotherapy. About 141 adults who had already completed 3 cycles of a bortezomib-based regimen took p…

This phase 2 trial tested the drug duvelisib (Copiktra) as a maintenance therapy after an autologous stem cell transplant in 17 people with T-cell lymphoma. The goal was to see if it could safely delay the cancer from coming back. The study was terminated early, so the full resul…

This study tested two experimental drugs, maplirpacept and glofitamab, given after a single dose of obinutuzumab, in adults with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatments. Participants had already tried at least two standard ther…

This pilot study tested the drug ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer had returned after a stem cell transplant. The goal was to see if the drug could safely bring about remission. However, the study was terminated e…

This study tested an experimental daily tablet called VTX002 in people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. About 213 participants were randomly assigned to receive one of two doses of VTX002 or a placebo for 13 weeks, with the option …

This phase 2 trial tested a combination of three drugs—ponatinib, venetoclax, and mini-hyper CVD chemotherapy—in people with relapsed or refractory T-cell acute lymphoblastic leukemia. The goal was to see if the combo could improve remission rates. However, the study was terminat…

This study looked at whether adding a drug called G-CSF to the usual treatment (ATG and Cyclosporin A) helps people with newly diagnosed severe aplastic anemia. Severe aplastic anemia is a rare condition where the bone marrow stops making enough blood cells. The trial included 20…

This study tested elranatamab, a bispecific antibody that helps the immune system attack cancer cells, in combination with other drugs for people with multiple myeloma that had stopped responding to at least three prior treatments. The trial aimed to find the safest dose and see …

This early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…

This study tested whether two drugs, daratumumab and pomalidomide, could help control multiple myeloma that came back after a stem cell transplant. It involved 13 adults whose cancer had relapsed. The goal was to see if the combination could lead to complete remission and delay t…

This very early study tested two drugs, alnuctamab and mezigdomide, together in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink tumors. However, the trial was stopped earl…

This early-phase trial tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in 110 adults with acute myeloid leukemia that had come back or not responded to treatment. The goal was to find the best dose and see if the combination could put the cancer into r…

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This early-phase study tested the safety of a drug called tazemetostat in people with a type of blood cancer called peripheral T-cell lymphoma that had returned or stopped responding to other treatments. Only 6 participants were enrolled before the study was stopped early. The go…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This early-stage study tested an oral drug called AUR104 in 9 adults with certain blood cancers (lymphomas and leukemia) that had come back or stopped responding to treatment. The main goal was to check the drug's safety and how the body processes it. The trial was terminated ear…

This study tested a new combination of drugs (polatuzumab vedotin plus standard chemotherapy) for patients with diffuse large B-cell lymphoma that came back or didn't improve after initial treatment. The trial aimed to see if this mix could shrink tumors better than standard ther…

This early-phase trial tested an experimental drug called IPH6501 in 23 people with certain types of Non-Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to check safety and find the right dose, while also looking for signs that the drug …

This study tested whether adding the targeted drug inotuzumab ozogamicin before and after a stem cell transplant could help control leukemia and lymphoma. It included 15 people aged 12 to 75 with certain blood cancers. The study was stopped early, but researchers looked at safety…

This study looked at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) when used in everyday medical practice in Russia. Only 6 adults took part, and the study was terminated early. Researchers measured whether patients' hemoglobin levels…

This early-phase trial tested a gene therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder that leaves boys unable to fight off bacteria and fungi. The treatment involved taking the patient's own blood stem cells, adding a corrected gene, and infusin…

This trial tested a gene therapy for X-linked chronic granulomatous disease (X-CGD), a rare genetic disorder that leaves boys unable to fight off infections. The treatment involved taking the patient's own blood stem cells, adding a working copy of the faulty gene, and returning …

This early study tested a new drug called CPO107 in 7 people with advanced CD20-positive Non-Hodgkin lymphoma who had no other good treatment options. The goal was to find a safe dose and see how the body handles the drug. The trial was stopped early, so we have limited informati…

This early-stage trial tested a new drug called gentulizumab in 58 people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had come back or stopped responding to treatment. Gentulizumab is an antibody that helps the immune system attack cancer cells. The m…

This study tested two different drug combinations given before a stem cell transplant for people with myeloid blood cancers like leukemia. One group got fludarabine and busulfan, the other got those drugs plus low-dose total body irradiation. The goal was to see which regimen led…

This early-stage trial tested a combination of two oral drugs, tazemetostat and venetoclax, in people with non-Hodgkin lymphoma that had come back or stopped responding to treatment. Only 3 people enrolled before the study was terminated. The main goals were to find the safest do…

This study tested whether giving two immunotherapy drugs (nivolumab and ipilimumab) after a stem cell transplant could safely help control high-risk multiple myeloma and lymphoma. It involved 46 adults aged 18-80 whose cancer was at high risk of coming back. The main goal was to …

This study tested a combination of chemotherapy drugs (cladribine, cytarabine, mitoxantrone, and G-CSF) in 53 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that had come back or not responded to prior treatment. The goal was to see how many …

This early-stage trial tested a drug called VAY736, alone or with other cancer drugs, in 18 adults with certain types of Non-Hodgkin Lymphoma that had come back or not responded to prior treatments. The main goals were to check safety and find the right dose. The study was termin…

This study tested a new drug called S227928, alone or with another drug (venetoclax), in people with certain blood cancers (AML, MDS/AML, or CMML) that returned or didn't respond to prior therapy. The goal was to find a safe dose and see if it helps. The trial was terminated earl…

This study tested the drug Spectrila (a form of L-asparaginase) in 40 adults aged 18-55 with newly diagnosed B-cell acute lymphoblastic leukemia. The goal was to see if the drug reached effective levels in the blood and to check its safety and immune response. The trial was termi…

This early-stage study tested an experimental drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find a safe dose and check for side effects. However, the study was stopped early after only 2 people enrolled, so no c…

This early-stage trial tested a new cell therapy called GDX012 in 16 people with acute myeloid leukemia (AML) that had come back or not responded to standard treatment. The main goals were to check safety, find the best dose, and see if the therapy could control the cancer. The s…

This study tested the long-term safety and effectiveness of a drug called CDZ173 in people with APDS/PASLI, a rare genetic condition that causes a weak immune system and swollen lymph nodes. The 37 participants had already taken CDZ173 or a similar drug in a previous study. The t…

This early-stage study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on multiple myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and infusing them back. The study included …

This early-stage trial tested a combination of two immune-boosting drugs—pembrolizumab (Keytruda) and CMP-001—in 14 adults with lymphomas that had come back or stopped responding to treatment. The goal was to find a safe dose that could shrink tumors. However, the study was termi…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This study looked at two different high-dose chemotherapy treatments for people aged 65 and older with multiple myeloma, a type of blood cancer. Participants received either the standard chemotherapy (melphalan) or a combination of melphalan and another drug (bortezomib) before a…

This study looked at whether taking a daily low-dose aspirin could help people with chronic kidney disease avoid their first heart attack or stroke. Over 4,600 participants were randomly assigned to take aspirin or receive usual care. The trial was stopped early, and the final re…

This study looked at the long-term safety of the drug osivelotor in people with sickle cell disease who had already taken it in an earlier trial. The goal was to track side effects and blood changes over time. However, the study was terminated early, so the full safety picture is…

This early-phase study tested an experimental drug called BR105 in 31 adults with advanced cancers that no longer responded to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was stopped early, so r…

This early-phase trial tested an oral drug called NMS-03592088 in 63 adults with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) that had come back or not responded to standard treatments. The goal was to check safety, find the right dose, and see if it cou…

This early-phase trial tested an experimental drug called voruciclib, either alone or combined with another drug (venetoclax), in adults with several types of blood cancers (like lymphoma, leukemia) that had come back or stopped responding to prior treatments. The main goal was t…

This study tested a new CAR-T cell therapy for people with multiple myeloma that had come back or stopped responding to treatment. The therapy uses a patient's own immune cells to target cancer cells. The trial was stopped early and only enrolled one person, so we have very limit…

This study tested a combination of two drugs, bintrafusp alfa and pimasertib, in people whose cancer had spread to the brain. The goal was to find the safest dose and see if the treatment could slow or stop the cancer from growing. The trial was stopped early after enrolling only…

This early-phase trial tested an experimental drug called SL-172154, given alongside standard chemotherapy drugs, for people with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals were to check safety and find the right dose. The study was…

This early-phase trial tested a new treatment called AUTO4 for people with a type of T-cell lymphoma that had come back or not responded to prior therapy. AUTO4 is a CAR T-cell therapy designed to recognize and attack cancer cells carrying a specific marker called TRBC1. The stud…

This early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help…

This study tested a drug called belantamab mafodotin (Blenrep) in 10 people with rare, aggressive lymphomas that had come back or not responded to treatment. The drug is an antibody-drug conjugate designed to target and kill lymphoma cells. The trial was terminated early, so the …

This phase 1 trial tested a two-step radioimmunotherapy (CD38-SADA and 177Lu-DOTA) in patients with relapsed or refractory non-Hodgkin lymphoma. The goal was to find safe doses and dosing schedules. Only 1 participant was enrolled, and the study was terminated early, so no conclu…

This study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce…

This early-phase trial tested a new therapy called ATA3219, which uses immune cells from a healthy donor to attack cancer cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study aimed to check safety and see if the treatment works, but it was stopped ea…

This phase II trial tested a combination of two drugs, venetoclax and decitabine, in 235 patients with certain blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) that had come back or not responded to treatment, as well as in older patien…

This study tested a daily pill called voxelotor in children aged 2 to 14 with sickle cell disease who had slightly abnormal blood flow in the brain. The goal was to see if the drug could improve that blood flow and reduce stroke risk. The trial was stopped early, but the results …

This phase 2 study tested a treatment called brexucabtagene autoleucel, a CAR T-cell therapy made from a patient's own immune cells, for four rare B-cell cancers: Waldenstrom macroglobulinemia, Richter transformation, Burkitt lymphoma, and hairy cell leukemia. The trial enrolled …

This study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.

This phase II trial tested adding asciminib (ABL001) to standard tyrosine kinase inhibitor therapy in 7 people with chronic myeloid leukemia who still had traces of cancer. The goal was to see if the combination could eliminate remaining cancer cells. The study was terminated ear…

This small Phase 2 trial tested two drugs — ibrutinib and pembrolizumab — in people with untreated high-risk chronic lymphocytic leukemia (CLL). The goal was to see if the combination could improve the body's immune function and shrink or control the cancer. However, the study wa…

This early-phase study tested two chemotherapy drugs, pevonedistat and belinostat, in 18 adults with acute myeloid leukemia or myelodysplastic syndrome that returned or didn't respond to prior treatment. The main goal was to find the safest dose and understand side effects. The s…

This study tested whether adding an extra drug (ALLO-647) to standard chemotherapy before a special immune cell treatment (CAR T) could help adults with a hard-to-treat type of lymphoma. Only 2 people joined before the trial was stopped early. The goal was to see if the new combi…

This study tested a drug called tislelizumab, which helps the immune system fight cancer, against standard chemotherapy in people with Hodgkin lymphoma that returned or didn't respond to treatment. Only 3 people took part before the study was stopped early. Because of this, we do…

This phase 2 study tested umbralisib (a PI3K blocker) plus rituximab (an antibody that targets B-cells) as the first treatment for people with follicular or marginal zone lymphoma. The goal was to see how many patients had their tumors disappear completely. Only 18 people enrolle…

This phase 2 trial tested a combination of two drugs, pembrolizumab (Keytruda) and rituximab (Truxima), in 22 people with marginal zone lymphoma, a type of blood cancer. The goal was to see if this chemotherapy-free approach could control the disease with fewer side effects than …

This study tested a drug called MBG453 in 10 people with a type of bone marrow disorder called lower-risk myelodysplastic syndromes (MDS). The goal was to see if the drug could improve blood cell counts and reduce the need for transfusions. The trial was terminated early, so the …

This study tested whether the drug anakinra could prevent severe brain inflammation (called ICANS) that sometimes happens after CAR T-cell therapy for certain types of lymphoma. The trial involved 23 adults whose lymphoma had returned or not responded to prior treatments. Researc…

This early-phase study tested a three-drug combination (uproleselan, azacitidine, and venetoclax) in older or medically unfit adults with untreated acute myeloid leukemia (AML). The goal was to find the safest dose and check for side effects. The study was stopped early, so resul…

This early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…

This study tested the drug pembrolizumab in people with a hard-to-treat type of lymphoma (DLBCL) that has certain genetic changes in the PD-L1 gene. The goal was to see if the drug could shrink tumors. However, the study was stopped early after enrolling only 5 participants, so t…

This study tested whether giving the drug caplacizumab based on regular blood tests (ADAMTS13 activity) could improve outcomes for adults with acquired thrombotic thrombocytopenic purpura (aTTP), a rare condition causing dangerous blood clots. The trial enrolled 58 adults and mon…

This study tested a drug called calaspargase pegol in adults aged 22 and older with a specific type of leukemia (Philadelphia-negative ALL). The goal was to find the right dose and check for side effects. The trial was stopped early, but researchers were looking at how the drug w…

This early-stage trial tested an oral drug called HMPL-523 in 69 people with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This study tested a combination of two drugs, venetoclax and azacitidine, for people with a high-risk type of bone marrow cancer called myelodysplastic syndrome (MDS) that either came back or didn't respond to treatment. The goal was to find the best dose and see how well it work…

This phase 2 trial tested inotuzumab ozogamicin (Besponsa) in children with B-cell acute lymphoblastic leukemia who had low levels of remaining cancer cells (MRD) despite treatment. The drug targets CD22, a protein on leukemia cells, and delivers a potent toxin. Only 5 children w…

This early-phase study tested a new treatment called LCAR-AMDR cells in 4 people with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment uses specially engineered immune cells to target two proteins (CLL1 and CD33) on leukemia cells. The…

This early-phase study tested whether a special type of cell (interferon gamma-primed mesenchymal stromal cells) could be safely given to prevent graft-versus-host disease, a common and serious complication after bone marrow transplant. Only 4 patients with acute leukemia or myel…

This early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…

This study tested a low-dose chemotherapy drug (decitabine) in people with a severe type of anemia that did not improve with standard treatments. Only 3 people were enrolled before the study was stopped early. The goal was to see if the drug could improve blood cell counts and re…

This study tested a new drug called CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to check safety, find the best dose, and see if the drug could shrink tumors. Th…

This early-phase trial tested a new drug called KRT-232 combined with three standard myeloma drugs (carfilzomib, lenalidomide, and dexamethasone) in 35 patients whose multiple myeloma had returned or stopped responding to treatment. The main goals were to check safety and find th…

This early-phase study tested the drug siltuximab in 6 adults with large granular lymphocytic leukemia (LGLL), a rare blood cancer. The goal was to see if the drug is safe and can shrink or control the disease. The study was terminated early, so results are limited.

This study tested a combination of two targeted drugs, tafasitamab and parsaclisib, in 54 adults with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal was to see if the combination was safe and could shrink tumors. However, the trial was termi…

This early-phase study tested two drugs, AZD1775 and belinostat, together in 20 adults with blood cancers like acute myeloid leukemia that had come back or not responded to treatment. The main goal was to find the safest dose and understand side effects. The study was stopped ear…

This early-phase study tested a new drug called modakafusp alfa combined with daratumumab in 15 people with multiple myeloma that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose. The trial was terminated early, so full…

This study tested a new drug called modakafusp alfa in 272 people with multiple myeloma that had returned or stopped responding to other treatments. The goal was to check safety and see if the drug could shrink tumors. The trial was terminated early, but researchers collected dat…

This early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve …

This small pilot study tested whether imatinib, a drug used for certain cancers, could reduce painful blockages in blood vessels (vaso-occlusive crises) in people with sickle cell anemia. Seven participants aged 18–25 took the drug for 6 months while researchers measured changes …

This early-stage trial tested a new drug called modakafusp alfa (TAK-573) combined with standard myeloma treatments in 15 adults with multiple myeloma. The main goal was to check safety and find the best dose. The study was terminated early, so we have limited information on how …

This early-stage study tested an experimental drug called HMPL-306 in 46 adults with advanced blood cancers (like leukemia) that have a specific genetic change called an IDH mutation. The goal was to find a safe dose and check for side effects. The study was stopped early, so res…

This study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.

This was a first-in-human study testing a single dose of an experimental drug called GSK4172239D in 11 people with sickle cell disease. The main goals were to check safety and how the drug moves through the body. The study was terminated early, so results are limited.

This study tested a new drug called DFP-10917 in adults with acute myeloid leukemia (AML) that had returned or not responded after 2 to 4 prior treatments. Participants received either DFP-10917 or one of several standard chemotherapy combinations. The goal was to see if DFP-1091…

This early-phase trial tested two immunotherapy drugs, ipilimumab and nivolumab, in people with HIV who had advanced solid tumors or Hodgkin lymphoma that had spread or come back. The goal was to find the safest dose and see if the combination could shrink tumors. The study was t…

This early-stage trial tested a new therapy for patients with acute myeloid leukemia (AML) that had returned or not responded to treatment. The therapy uses a patient's own immune cells, genetically modified to recognize and attack cancer cells carrying a specific marker (CD123).…

This study aimed to see if a new medicine (efanesoctocog alfa) helps people with moderate or severe hemophilia A reach their personal goals and be more physically active. It planned to enroll 35 people aged 12 to 50, but was stopped early after only 3 joined. The medicine is used…

This study tested whether the antibiotic ceftolozane-tazobactam, guided by a rapid molecular test, could effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. The 17 participants received the antibiotic t…

This study tested two extra care programs—supportive palliative care and clinical management of other health issues—for older or frail patients who had a donor stem cell transplant. The goal was to see if these programs could improve quality of life and survival compared to stand…

This phase 2 trial tested a new drug called sabatolimab combined with two other drugs (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination could help patients achieve r…

This phase 2 study tested a new CAR-T cell therapy called PHE885 in adults with relapsed and refractory multiple myeloma. The therapy targets a protein called BCMA on myeloma cells. The trial aimed to see how many patients responded, but it was terminated early. Results may still…

This study tested whether adding sabatolimab to standard chemotherapy (azacitidine) helps people with high-risk myelodysplastic syndrome (MDS) or a related leukemia (CMML-2). The trial aimed to see if the combination improved survival. However, the study was stopped early, so we …

This early-phase study aimed to see if combining two immune-stimulating drugs (rintatolimod and interferon alpha-2b) could help cancer patients fight off COVID-19. Only 4 people took part before the study was stopped early. The main goals were to check safety and measure how the …

This study tested adding an experimental drug called MBG453 to standard chemotherapy for people with a serious bone marrow disorder called myelodysplastic syndrome (MDS). The trial included 127 adults with high-risk MDS who could not have a stem cell transplant. The goal was to s…

This study tested a new, easy-to-dissolve malaria tablet in infants and newborns weighing less than 5 kg who had uncomplicated malaria. The goal was to see how the medicine worked in the body, how safe it was, and how well it treated the infection. The trial was stopped early aft…

This early-phase study tested a personalized cell therapy (CAR-T) for people with B-cell acute lymphoblastic leukemia that returned or didn't respond to standard treatments. The therapy used the patient's own immune cells, modified to target two markers (CD19 and CD20) on leukemi…

This early-phase trial tested a gene-edited stem cell product called OTQ923 in 4 people with severe sickle cell disease. The goal was to boost fetal hemoglobin to reduce painful crises and other complications. The study was terminated early, so we have limited data on safety and …

This phase 2 trial tested a combination of three oral drugs—decitabine, cedazuridine, and venetoclax—in adults whose acute myeloid leukemia (AML) came back after a donor stem cell transplant. The goal was to see if the drugs could kill cancer cells and achieve a complete remissio…

This study tested the safety and effectiveness of the drug umbralisib in 12 people with chronic lymphocytic leukemia (CLL) who had not received prior treatment. The goal was to see how many patients had their cancer shrink or disappear. The study was stopped early, but results st…

This early-phase study tested the safety and best dose of a drug called Minnelide in 27 adults with acute myeloid leukemia (AML) that had returned or not responded to prior therapy. The goal was to find the highest safe dose and check for side effects. The study was terminated ea…

This study tested two experimental drugs, TQ05105 and TQB3909, taken together as tablets for people with moderate- to high-risk myelofibrosis, a rare bone marrow disorder. The goal was to see if the combination could shrink an enlarged spleen and improve symptoms. The trial enrol…

This study tested a drug called selinexor combined with chemotherapy or another drug (tislelizumab) in people with relapsed or hard-to-treat T and NK cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early, so results ar…

This study tested a drug called gilteritinib, which targets a specific genetic change in leukemia cells, combined with standard chemotherapy in children and young adults (ages 6 months to 21 years) whose acute myeloid leukemia (AML) had returned or not responded to treatment. The…

This study looked at whether a donor stem cell transplant (allogeneic) works better than standard drug therapy for people with multiple myeloma that came back after initial treatment. It included adults aged 18-70 with a compatible donor. The trial was stopped early, so results a…

This phase II trial tested a combination of two drugs—daratumumab and ibrutinib—in people with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to treatment. The goal was to see if the combo could shrink or eliminate cancer better than ibrutinib alone. …

This study tested a two-drug combination (ibrutinib and venetoclax) in 30 adults with chronic lymphocytic leukemia (CLL) that had returned or stopped responding to prior treatments. The goal was to see if starting with ibrutinib alone, then adding venetoclax, could safely clear t…

This early-phase trial tested a new drug called TQB3909 in 19 people with mantle cell lymphoma that had returned or stopped responding to treatment. The goal was to find a safe dose and check for side effects. However, the study was terminated early, so we have limited informatio…

This study followed 265 people with sickle cell disease who were taking Oxbryta (voxelotor) as part of their normal care. Researchers wanted to see how the drug affected hemoglobin levels, sickle cell complications, and overall health over up to 5 years. The study was observation…

This early-stage study tested a new drug called WVT078, alone or with another drug (WHG626), in 56 people with multiple myeloma that returned or didn't respond to at least two prior treatments. The main goal was to find a safe dose and check for side effects. The study was termin…

This study tested a new drug called SAR444245, alone or with pembrolizumab, in 14 people aged 12 and older with B cell lymphoma that came back or didn't respond to treatment. The goal was to see if the drug could shrink tumors. The study was terminated early, so results are limit…

This early-phase trial tested an experimental drug called CWP232291 combined with the standard chemotherapy cytarabine in 15 adults with acute myeloid leukemia (AML) that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for signs of…

This study tested a single injection of fibrinogen concentrate followed by a platelet transfusion in blood cancer patients with severe bleeding who did not respond to standard platelet transfusions. The goal was to see if it improved blood clotting. However, the trial was termina…

This early-stage study tested a new treatment called CNTY-101 for people with B-cell cancers that came back or didn't respond to other therapies. The main goals were to find a safe dose and see if the treatment could shrink tumors. The study was stopped early, so results are limi…

This study looked at the long-term safety of dexpramipexole in adults with severe eosinophilic asthma. Participants had already completed earlier phase 3 trials. The goal was to track side effects and asthma control over time. However, the study was terminated early, which may li…

This study tested a daily pill called dexpramipexole in 654 people with severe eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. The goal was to see if the drug could reduce severe asthma attacks over a year. However, the trial was terminat…

This small early-phase trial tested whether adding pirtobrutinib to venetoclax could wipe out leftover cancer cells in people with CLL/SLL who still had detectable disease after venetoclax alone. Only 3 people enrolled before the study was terminated, so we cannot draw any reliab…

This study tested a new drug called SAR443579 in adults and children with certain blood cancers that had come back or not responded to treatment. The goal was to see if the drug was safe and could shrink or control the cancer. The trial was stopped early, so results are limited.

This study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells…

This Phase 3 trial tested dexpramipexole, an oral drug, in over 1,000 people with severe eosinophilic asthma that was not well controlled by standard treatments. The goal was to see if it could reduce severe asthma attacks over a year. However, the study was terminated early, so …

This study looks at the long-term safety of inclacumab in people with sickle cell disease who have already taken the drug in a previous study. It tracks side effects and how often pain crises occur. The goal is to see if long-term use is safe and helps control the disease.

This early-phase study tested a combination of high-dose chemotherapy (melphalan) and escalating doses of total bone marrow irradiation, followed by a stem cell rescue, in 13 people with multiple myeloma that had returned after initial treatment. The goal was to find the highest …

This study looked at whether voxelotor, a daily pill for sickle cell anemia, can improve blood flow and oxygen supply to the brain in children. The trial planned to enroll 22 participants aged 4 to 30 years with a severe form of sickle cell disease. However, the study was termina…

This study tested a drug called ADCT-602 in 37 people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that had returned or stopped responding to other treatments. The drug is a lab-made antibody that targets a protein (CD22) on cancer cells to stop them from gro…

This study tested a drug called narsoplimab (OMS721) for atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots and organ damage. The trial aimed to see if the drug could improve platelet counts and was safe for adults and adolescents. However, the st…

This study tested the drug ponatinib in 51 adults with a fast-growing form of chronic myeloid leukemia (CML) who had little or no prior treatment. The goal was to see if ponatinib could control the disease by blocking a protein that drives leukemia growth. However, the drug can c…

This study tested whether combining venetoclax with either azacytidine or a DA chemotherapy regimen could prevent relapse in acute myeloid leukemia patients who still have detectable cancer cells (MRD positive) after standard treatment. The trial planned to enroll 20 adults in co…

This study tested a drug called fostamatinib to help people whose blood cell counts drop after a stem cell transplant. The goal was to see if the drug could raise red blood cells or platelets without needing transfusions. The trial was stopped early after enrolling only one perso…

This early-phase trial tested a combination of two drugs, parsaclisib and chidamide, in 12 people with relapsed or refractory peripheral T-cell lymphoma. The goal was to find a safe dose and see if the combination could shrink tumors. The study was terminated early, so results ar…

This early-phase trial tested the drug fedratinib (Inrebic) as a maintenance therapy to prevent relapse in people with myeloproliferative neoplasms after a stem cell transplant. Only 12 participants were enrolled before the study was terminated. The goal was to find a safe dose a…

This study tested two oral drugs, eltanexor and Inqovi, in adults with high-risk myelodysplastic syndromes (MDS) that did not improve with standard treatment. MDS is a bone marrow disorder that can lead to leukemia. The goal was to find a safe dose and see if the combination help…

This early-phase trial tested a new cell therapy called LUCAR-G39P in 11 patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The therapy uses a patient's own immune cells, modified to attack two targets (CD19 and CD20) on cancer cells. The main goals were to check s…

This phase 2 trial tested two drugs, CB-103 and venetoclax, in adolescents and young adults with T-cell acute lymphoblastic leukemia (T-ALL) that had come back or not responded to treatment. The goal was to see if the combination could control the disease. However, the study was …

This early study tested a new treatment called Descartes-15 for people with multiple myeloma that came back or didn't respond to standard therapies. Descartes-15 uses a patient's own immune cells, engineered to recognize and attack myeloma cells. The trial was very small (4 parti…

This study tested an experimental drug called VLX-1005 in people with a rare condition where the blood thinner heparin causes a dangerous drop in platelets (cells that help blood clot). Participants received either VLX-1005 or a placebo alongside standard care. The goal was to se…

This phase 2 study tested a combination of two drugs, lenalidomide and rituximab, in 30 people with previously untreated indolent non-Hodgkin's lymphoma. The goal was to see how well the drugs worked together to shrink or control the cancer. Participants took lenalidomide daily f…

This early-phase study tested an experimental drug called BR108 in 8 adults with advanced blood cancers (lymphoma, leukemia, or myelodysplastic syndrome) that had not responded to prior treatments. The drug was given by IV infusion twice per cycle. The main goals were to check sa…

This study tested whether doing an early endoscopic ultrasound and removing any gallstones from the bile duct could help people with severe pancreatitis caused by gallstones. The trial planned to enroll many patients but was stopped early after only 27 participants. The main goal…

This study looked at the long-term safety of voxelotor (a daily pill) in 179 people with sickle cell disease who had already taken it in a previous trial. Participants continued taking the drug and were monitored for side effects and complications like pain crises. The trial was …

This study tested a new oral drug called narazaciclib combined with dexamethasone in people with multiple myeloma that returned or didn't respond to treatment. The goal was to find a safe dose and see if it could shrink the cancer. Only 2 patients were enrolled before the study w…

This phase II study tested the immunotherapy drug pembrolizumab (Keytruda) in 9 people with untreated follicular lymphoma or marginal zone lymphoma. The goal was to see if the drug could shrink tumors or slow the disease. However, the trial was terminated early, so we have very l…

This early-stage study tested the drug belantamab mafodotin (Blenrep) as a maintenance therapy to prevent multiple myeloma from returning after a stem cell transplant. Only 6 people took part before the study was stopped early. The main goals were to check safety and pain levels,…

This study looked at the long-term safety of the drug voxelotor in 162 people with sickle cell disease who had already taken it in earlier trials. Everyone received voxelotor once daily. The main goal was to track side effects. The trial was terminated early, so the full safety p…

This early-stage trial tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine and venetoclax) in 25 people with relapsed or hard-to-treat acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia. The study aimed to check…

This study tested a bone marrow transplant using a partially matched family donor for people with blood cancers like leukemia. The goal was to see if a milder conditioning regimen and a drug called cyclophosphamide could help patients survive at least 180 days after transplant. T…

This study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early…

This phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…

This study tested whether adding an experimental drug (INCB001158) to a standard therapy (daratumumab) could help people with multiple myeloma that returned or didn't respond to prior treatments. The trial enrolled 15 adults who had already tried at least 3 other therapies. The g…

This study tested a new drug called INCB059872 in people with advanced solid tumors or blood cancers that had not responded to standard treatments. The goal was to find a safe dose and see if it could control the disease. The trial was stopped early, so results are limited.

This early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and se…

This study tested a treatment called MT-401, which uses specially trained immune cells from a donor to fight acute myeloid leukemia (AML) after a stem cell transplant. The goal was to see if these cells could prevent or treat relapse. The trial enrolled 92 people but was stopped …

This study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…

This phase 2 trial tested a drug called P1101 (a type of interferon) in 11 people with early myelofibrosis, a rare bone marrow disorder. The goal was to see if the drug could shrink the spleen, improve symptoms, or boost blood counts. The study was terminated early, so the full r…

This early-stage study tested a new type of CAR-T cell therapy (ASP2802) for people with B-cell lymphoma that came back or stopped responding to treatment. The therapy uses a person's own immune cells, modified to better fight cancer, plus a booster protein. The study was termina…

This study tested a new treatment called CTX110 for people with B-cell blood cancers that came back or didn't respond to standard therapy. CTX110 uses donor immune cells that are edited with CRISPR technology to target and attack cancer cells. The trial enrolled 93 adults and aim…

This study looked at the long-term safety of BCX9930, an oral medication, for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants and aimed to monitor side effects. The study was terminated…

This phase 2 trial tested a daily pill called etavopivat in 17 adults with very low, low, or intermediate risk MDS who had anemia. The goal was to see if the drug could improve red blood cell counts and reduce the need for transfusions. The study was terminated early, so the full…

This study tested a combination of four drugs (daratumumab, ixazomib, pomalidomide, and dexamethasone) in 23 people with multiple myeloma that had come back or stopped responding to earlier treatments. The goal was to see how many patients' tumors shrank or disappeared. The study…

This early-phase trial tested whether adding the drug itacitinib to standard immune-suppressing medications could help prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. The study enrolled 84 participants with leukemia, lymphoma,…

This study tested a daily pill called INCB000928 for people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. The goal was to see if it was safe and could raise red blood cell levels, reducing the need for transfusions. The trial was terminated early afte…

This phase 3 trial tested whether adding parsaclisib to the standard drug ruxolitinib could better shrink the spleen and ease symptoms in people with myelofibrosis. The study enrolled 252 participants but was terminated early, so the full results are not available. The goal was t…

This early-phase study tested a new treatment called bbT369 for people with a type of blood cancer (B cell non-Hodgkin's lymphoma) that had come back or stopped responding to other treatments. The therapy uses a patient's own immune cells, which are modified to better recognize a…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…

This early-phase trial tested two lab-made antibodies, magrolimab and mogamulizumab, together in people with a type of T-cell lymphoma (mycosis fungoides or Sezary syndrome) that had returned or stopped responding to prior treatments. The goal was to find the best dose and see if…

This phase 2 study tested adding sabatolimab, an experimental immunotherapy, to standard chemotherapy drugs (azacitidine, decitabine, or oral decitabine) in 39 adults with intermediate to very high risk myelodysplastic syndrome (MDS). The main goal was to check safety, and the tr…

This study tested a drug called sabatolimab, alone or with another drug, in 24 adults and teens with acute myeloid leukemia (AML) who had signs of leftover cancer after a stem cell transplant. The goal was to see if it could prevent the cancer from coming back without causing sev…

This early-phase study tested a new treatment for children and young adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The treatment involved taking patients' own immune cells, engineering them to recognize and attack leukemia cells (CA…

This early-stage trial tested two new drug combinations in 52 adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). One group received HDM201 plus MBG453, the other HDM201 plus venetoclax. The main goal was to check safety and find the right dose. …

This phase 2 trial tested a new drug called sabatolimab, combined with two standard chemotherapy drugs (azacitidine and venetoclax), in 20 adults with high or very high risk myelodysplastic syndromes (MDS) who could not have intensive chemotherapy or a stem cell transplant. The g…

This early-phase study tested combinations of three antibody drugs (sabatolimab, NIS793, and canakinumab) in 33 adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. The main goal was to check safety and find the right doses. The study was terminated early, so …

This early-stage trial tested a combination of two experimental drugs, VOB560 and MIK665, in 37 people with relapsed or refractory non-Hodgkin lymphoma, acute myeloid leukemia, or multiple myeloma. The drugs aim to block proteins that help cancer cells survive, forcing them to di…

This early-stage study tested a new drug called JBH492 in 25 people with two types of blood cancer (chronic lymphocytic leukemia and non-Hodgkin's lymphoma) that had returned or stopped responding to standard treatments. The main goal was to check the drug's safety and find the r…

This phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…

This study tested an experimental drug called AMG 701, alone or with other medicines, in 174 adults with multiple myeloma that returned or didn't respond to prior treatments. The main goals were to check safety and find the best dose. The trial was stopped early, so results are l…

This early-phase study tested a new drug called tasquinimod, alone or with standard chemotherapy, in 30 adults with multiple myeloma that had relapsed or become resistant. The main goal was to find a safe dose and check for side effects. The trial was terminated early, so results…

This early-phase trial tested a new drug called BMS-986253, alone or with standard chemotherapy, for people with myelodysplastic syndromes (MDS), a group of bone marrow disorders. The study aimed to find a safe dose and see if the drug could shrink cancer. However, the trial was …

This study tested a treatment called TCB008, made from donated immune cells, for adults with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. The goal was to see if it could reduce cancer cells in the bone marrow. The trial was stopped early, but…

This study looked at a new way to prevent severe graft-versus-host disease (GVHD) in children who had a bone marrow transplant for blood cancers. The goal was to see if stopping certain immune-suppressing drugs after day 60 could lower the risk of severe GVHD. Only 3 children too…

This study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The s…

This study tested the drug eltrombopag in 9 people whose bone marrow did not recover well after a stem cell transplant for leukemia. The goal was to see if the drug could increase platelet counts and reduce the need for transfusions. The study was stopped early, so results are li…

This study tested whether adding the experimental drug parsaclisib to the standard drug ruxolitinib helps people with myelofibrosis whose spleen and symptoms haven't improved enough on ruxolitinib alone. The main goal was to see if the combination could shrink the spleen by at le…

This study tested a targeted cancer drug called ponatinib combined with standard chemotherapy in children and young adults up to age 21 with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that had come back or stopped responding to other treatments. The g…

This study tested the drug ofatumumab (Arzerra) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who still had signs of disease after chemotherapy. The goal was to see if the drug could clear remaining cancer cells and keep the disease under c…

This early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the…

This early-stage study tested a new drug called CC-95251, alone or with other cancer drugs, in people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that had come back or not responded to treatment. The main goals were to check safety and find the right dose…

This pilot study looked at whether radiation therapy could help people with lymphoma that did not respond to CAR T cell therapy. Only 3 participants were enrolled before the study was terminated. The main goal was to check safety and side effects of adding radiation shortly after…

This early-stage trial tested an experimental oral drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). The main goals were to check safety and find the right dose. However, the study was terminated e…

This early-stage trial tested two drugs, isatuximab and cemiplimab, together in 58 people with relapsed or refractory lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study was terminated early, so while some safety and response data were col…

This early-phase trial tested a CAR T cell therapy called bb2121 (ide-cel) combined with other drugs in 21 adults with relapsed or refractory multiple myeloma. The goal was to find a safe dose and see if the combinations could shrink tumors. The study was terminated early, so res…

This study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. Only 9 participants were enrolled, and the study was terminated early. The goal was to see if the drug is sa…

This early-phase trial tested a drug called AMG 420 in 23 people with multiple myeloma that had returned or stopped responding to at least three prior treatments. Participants received the drug as a continuous 28-day IV infusion. The study aimed to find the safest dose and check …

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…

This trial tested the drug isatuximab, a targeted antibody, combined with standard chemotherapy in children aged 28 days to under 18 years whose acute leukemia had returned or stopped responding to treatment. The study aimed to see if the combination could help more children achi…

This phase 2 trial tested a drug called PF-05212384 in 10 people with certain types of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), including cases linked to past cancer treatment or that had come back after other therapies. The drug was given weekly through an…

This study tested a CAR T-cell therapy called axicabtagene ciloleucel in patients with a rare type of lymphoma (PMBCL) that had come back or not responded to initial treatment. The goal was to see if it could shrink tumors and improve outcomes. However, the trial was terminated e…

This early-phase trial tested the drug pomalidomide in 15 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or was not responding to prior treatments. The goal was to find the safest dose and see how the drug affects the immune system and cancer gro…

This early-phase trial tested a combination of three drugs—maplirpacept, tafasitamab, and lenalidomide—in 6 people with diffuse large B-cell lymphoma (DLBCL) that had returned or not responded to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy…

This Phase II study tested a radioactive tracer called 68GaNOTA-Anti-MMR-VHH2 to see if it can light up certain immune cells (macrophages) on PET scans. The trial included 29 people with head and neck cancer, lymphoma, atherosclerosis, or sarcoidosis. The goal was to see if the t…

This pilot study tested whether a special PET scan (FDG-PET/CT) can detect hidden heart inflammation in cancer patients receiving immune checkpoint inhibitors (ICIs). The goal was to catch this inflammation early, before it becomes severe. Only 2 participants were enrolled, and t…

This phase 3 trial tested a new radioactive imaging agent called [68Ga]Ga-PentixaFor to see if it could better detect lymphoma tumors compared to the standard PET scan. The study aimed to enroll adults with marginal zone lymphoma who had not yet been treated. However, the trial w…

This study tested whether a wearable EEG device can help doctors diagnose Alzheimer's disease and mild cognitive impairment. Researchers compared brain wave data from the EEG with standard memory and thinking tests in 148 participants. The goal was to see if the EEG could improve…

This study compared a new device, the Proxima 3®, to standard hospital equipment for measuring blood gases like oxygen and carbon dioxide. Researchers wanted to see if the new device was accurate and fast in patients whose condition was changing quickly. The trial was stopped ear…

This study tested whether a special PET scan using a tracer called 68Ga-PentixaFor could predict how well patients with central nervous system lymphoma respond to chemotherapy. The plan was to scan patients before, during, and after treatment and see if the scan results matched t…

This pilot study tested the blood pressure drug telmisartan (Micardis) to prevent acute graft-versus-host disease (GVHD) in people receiving a stem cell transplant for blood cancers. The trial aimed to enroll 60 participants but was terminated early with 32. Researchers tracked s…

This study tested a drug called RLYB212 in pregnant women at high risk for a condition where the mother's immune system attacks the baby's platelets, causing dangerous bleeding. The goal was to see if the drug was safe and how it moved through the body. Only one woman enrolled be…

This study tested whether a non-invasive breathing machine (ventilation) could prevent acute chest syndrome, a serious lung complication, in children with sickle cell disease who were hospitalized for severe pain. The standard prevention is spirometry, which requires active deep …

This study looked at whether blowing a fan with aromatherapy on the face can help reduce breathlessness in people with terminal illness. The trial planned to enroll 26 adults who were near the end of life and had trouble breathing. Participants were randomly assigned to receive a…

This study tested a nasal spray containing a strong painkiller (sufentanil) for adults with sickle cell disease experiencing a painful crisis. The goal was to see if it could provide faster relief than the standard gas mixture (EMONO) before giving morphine through an IV. The tri…

This study looked at whether a supervised exercise program could help improve quality of life and reduce fatigue in people under 65 with multiple myeloma who had a stem cell transplant. Participants were randomly assigned to either an exercise group or a control group. The study …

This Phase 2 trial tested whether FSD201 tablets could reduce chronic pain in adults with mast cell activation syndrome. The study planned to enroll many participants but was terminated early with only 2 people. No results are available to show if the drug works or is safe.

This study tested whether a digital platform could improve collaborative care for depression in cancer patients. About 300 adults receiving cancer treatment with significant depression symptoms were enrolled. The platform aimed to help care managers track symptoms and coordinate …

This study tested whether a simple, 5-minute daily breathing exercise using a handheld device, combined with a personalized exercise plan, could improve heart health and fitness in people who have survived lymphoma. Only one person enrolled before the study was stopped, so no mea…

This study tested a smartphone app called HeartPhone that appears on the lock screen to encourage physical activity in breast cancer, leukemia, and lymphoma survivors. Participants used the app for 3 months and wore a Fitbit to track activity. The goal was to see if the app could…

This study tested two educational programs for parents with late-stage cancer who have children aged 5 to 17. The programs were designed to improve parent-child relationships and boost parents' confidence in talking about cancer with their kids. Researchers hoped to reduce anxiet…

This study tested a sensory rehabilitation program for people who lost their sense of smell or taste after chemotherapy for blood cancers like multiple myeloma or lymphoma. The program involved exercises to retrain the nose and tongue. Only 5 people enrolled before the study ende…

This phase 2 trial tested whether levocarnitine and vitamin B complex could help lower high liver enzyme levels caused by chemotherapy drugs in adults with acute lymphoblastic leukemia. The study planned to enroll 10 participants but was terminated early. The goal was to see if t…

This study looks at how the drug luspatercept is used in real-world clinics for patients with lower-risk myelodysplastic syndromes (MDS) or beta-thalassemia. Researchers will track patient characteristics, treatments, and outcomes like reduced need for blood transfusions. The goa…

This study tests whether a personalized exercise program (aerobic and resistance training) done before CAR-T therapy can improve physical fitness and quality of life in older adults (60+) with multiple myeloma that has returned or stopped responding to treatment. Twenty participa…

This study aimed to collect real-world data on Netherton Syndrome, a rare genetic skin disorder. Researchers planned to follow 4 participants over 52 weeks, measuring skin severity and other symptoms. The study was terminated early, so results are limited.

This study looked at how patients with hemophilia A or those on blood thinners feel about monitoring their blood clotting at home. Researchers interviewed 19 people to understand their needs and hopes for a new device that could measure clotting factors. The goal was to gather in…

This early-stage study is testing a new drug called pociredir in 24 adults with sickle cell disease. Researchers want to see how the drug moves through the body and whether taking it with food changes its effects. The goal is to gather safety and dosing information, not to treat …

This study aimed to find genetic mutations in people with idiopathic cytopenia of undetermined significance (ICUS), a condition of unexplained low blood cell counts. Researchers wanted to see if these mutations are similar to those found in myelodysplastic syndrome (MDS), a type …

This pilot study aimed to see if a blood test called thromboelastography (TEG) and platelet mapping could predict clotting or bleeding complications after non-cardiac surgery. The study included 200 patients who were taking aspirin or clopidogrel for at least 10 days before elect…

This study looked at why minority cancer patients often don't take part in clinical trials. Researchers surveyed patients about their understanding and attitudes, then tested an educational video and booklet to see if it boosted enrollment. The goal was to create a personalized p…

This study aimed to find out how common antibiotic resistance is in multiple myeloma patients receiving a stem cell transplant. Researchers planned to collect data from 124 adults to help design future studies on preventing infections. The study was stopped early, so results are …

This study aimed to see if a sensitive molecular test could predict relapse in adults with acute myeloid leukemia (AML) who had a stem cell transplant. Researchers planned to follow 303 patients in remission, comparing outcomes between those with and without detectable disease ma…

This study tested whether consumer movement trackers could provide a more precise measure of cancer patients' physical abilities than the standard ECOG score, which relies on a doctor's observation. Researchers enrolled 41 cancer patients and used a Kinect device to record their …

This study looked at how well the COVID-19 vaccine works in adults with B-cell non-Hodgkin lymphoma, especially those who received a common treatment called anti-CD20 monoclonal antibodies in the past year. Researchers compared antibody and T-cell responses between treated and un…

This study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—could predict if a person with polycythemia vera would stop responding to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first t…

This pilot study tested a decision aid designed to help older adults with early dementia or depression think about safer ways to store firearms at home. Only 5 people took part, and the study was ended early. The goal was to see if the tool was practical and acceptable, and wheth…

This study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …

This study was a large registry that followed over 3,000 people newly diagnosed with multiple myeloma to understand how the disease is managed in everyday practice. Participants received standard treatments prescribed by their own doctors, and researchers collected information on…

This very early study aimed to compare an oral (pill) version of the chemotherapy drug cladribine with the standard IV (vein) version in people with certain leukemias. Only 3 people took part before the study was stopped early. The main goal was to see how the body handles the or…

This study aimed to see if women with thrombophilia (a condition that makes blood clot more easily) have differences in artery function compared to healthy women. Researchers planned to measure blood vessel dilation and other artery health markers. However, the study was terminat…

This study aimed to find out why some multiple myeloma patients develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved finger device called EndoPAT to check blood vessel health and tracked symptoms through surveys. The study enrolled 50 adu…

This study aimed to understand why some people taking the cancer drug ibrutinib develop heart issues like atrial fibrillation (irregular heartbeat) and high blood pressure. Researchers planned to follow 8 patients with blood cancers, using heart tests and blood markers to try to …

This study tested whether ultrasound can reliably show if a critically ill child's stomach is empty before removing their breathing tube. Researchers monitored 34 children in intensive care, scanning their stomachs multiple times over 12 hours after stopping feeding. The goal was…

This study looked at how moderate or severe liver problems change the amount of the cancer drug oral azacitidine in the blood. It was designed for adults with certain blood cancers. The study was stopped early after only 2 people enrolled, so the results are very limited.

This study tested a method that uses real-time imaging to guide a minimally invasive surgical tool for taking lymph node samples from the abdomen. The goal was to see if this approach could make the biopsy more accurate and reduce risks compared to standard surgery. The study inc…

This study aimed to see how often people with chronic hepatitis C have a blood condition called monoclonal B-cell lymphocytosis (MBL), and whether treating hepatitis C affects MBL. Researchers planned to enroll 29 participants and compare blood samples before and after hepatitis …

This study looked at why erythropoietin (EPO), a drug used to treat anemia, can raise blood pressure in people with chronic kidney disease. Researchers planned to enroll 160 participants but stopped early with only 27. The goal was to measure changes in blood pressure and blood v…

This study looked at how healthy brothers and sisters of children with blood cancer felt about the information they got about the disease. Researchers interviewed 7 children aged 6 to 12 to understand their satisfaction and what they thought about the illness. The goal was to imp…

This study aimed to find how often IDH1 and IDH2 gene mutations occur in adults with acute myeloid leukemia (AML) in China, and whether those mutations affect a patient's chance of relapse or survival. Researchers planned to analyze stored leukemia samples from over 1,000 patient…

This observational registry aims to learn about the health, wellbeing, and needs of people who were diagnosed with cancer between ages 18 and 39. Participants complete surveys every 6 to 12 months about anxiety, depression, social support, and financial distress. The registry als…

This study looked at whether proteins that control our body's daily rhythms (clock proteins) can predict how severe asthma will get. Researchers monitored these proteins in the blood and sputum of 50 adults with severe eosinophilic asthma before and during treatment with mepolizu…

This study aimed to track four bone-related markers in the blood and urine of multiple myeloma patients receiving standard bisphosphonate therapy. Only 3 people enrolled before the study was terminated. It was designed to observe changes over 12 months, not to test a new treatmen…